Source link : https://www.newshealth.biz/health-news/tyk2-inhibitor-shows-promise-for-moderate-severe-psoriasis/
TOPLINE: Zasocitinib , a tyrosine kinase 2 (TYK2) inhibitor, at oral doses of ≥ 5 mg led to greater skin clearance than placebo over a period of 12 weeks, in a phase 2b study. METHODOLOGY: Researchers performed a phase 2b, randomized, double-blind trial to assess the efficacy, safety, and tolerability of different doses of zasocitinib […]
Author : News Health
Publish date : 2024-08-26 10:44:57
Copyright for syndicated content belongs to the linked Source.
Categories